Skip to main content
. 2020 Dec 23;14(3):235–240. doi: 10.1007/s12254-020-00669-y

Table 2.

Demographic and clinical characteristics of patients diagnosed with multiple myeloma according to blood groups

Clinical features A (n = 92) 0 (n = 49) B (n = 38) AB (n = 19) P P A vs. non‑A P 0 vs. non‑0 P B vs. non‑B P AB vs. non-AB
Gender F/M n/n, (%/%) 49/43 (53.3/46.7) 24/25 (49.0/51.0) 13/25 (34.2/65.8) 6/13 (31.6/68.4) 0.121 0.087 0.742 0.105 0.228
Age med. at the time of diagnosis 62 (36–90) 63 (32–87) 66 (41–79) 62 (41–79) 0.548 0.636 0.809 0.166 0.487
Heavy chain type n (%) 0.039 0.021 0.379 0.277 0.479
G 50 (54.3) 24 (49.0) 26 (68.4) 11 (57.9)
A 32 (34.8) 14 (28.6) 4 (10.5) 2 (10.5)
M 0 (0) 1 (2.0) 0 (0.0) 0 (0.0)
Non‑G, A, M 10 (10.9) 10 (20.4) 8 (21.1) 6 (31.6)
Light chain type n (%) 0.048 0.032 0.059 0.748 0.092
K 59 (64.1) 20 (40.8) 22 (57.9) 8 (42.1)
L 33 (35.9) 28 (57.1) 16 (42.1) 10 (52.6)
Non‑K, L 0 (0.0) 1 (2.1) 0 (0.0) 1 (5.3)
LDH> normal n (%) 23 (25.0) 23 (46.9) 9 (23.7) 6 (31.6) 0.039 0.123 0.007 0.333 1.000
Beta‑2 microglobulin med 4.69 (1.2–59.4) 5.51 (1.51–42.3) 4.49 (1.8–61.3) 5.64 (1.6–27.3) 0.654 0.223 0.129 0.841 0.671
Hypercalcemia n (%) 11 (12.0) 9 (18.4) 3 (7.9) 3 (15.8) 0.509 0.679 0.227 0.424 0.721
Renal Impairment n (%) 21 (22.8) 17 (34.7) 8 (21.1) 8 (42.1) 0.163 0.204 0.198 0.420 0.173
Anemia n (%) 64 (69.6) 41 (83.7) 24 (63.2) 15 (78.9) 0.363 0.403 0.132 0.271 0.789
Lytic lesion n (%) 80 (87.0) 42 (85.7) 30 (78.9) 17 (89.5) 0.637 0.688 1.000 0.211 1.000
Extramedullary lesion n (%) 8 (8.6) 17 (34.7) 3 (7.9) 2 (10.5) 0.000 0.082 0.000 0.305 1.000

F Female, M Male, Med median, K Kappa, L Lambda, LDH Lactate dehydrogenase